

Press Release

Media Contact: Wilhelm Haselmeier GmbH & Co. KG
Vaihinger Straße 48
70567 Stuttgart
Germany

Dr. Fred Metzmann
Chief Business Officer
☎ +49 711 71978 163
✉ f.metzmann@haselmeier.com

A further hit model: The Pergoveris® Pen for Merck

Stuttgart, Germany, 31 July 2017

Haselmeier has a worldwide reputation for its patient-friendly, high-tech innovations. The new Pergoveris® Pen, developed for its customer Merck, has once again confirmed the company's high standard of development.

The leading science and technology company Merck announced recently *"that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has given a positive assessment of the new Pergoveris® pen in an official statement"*.

Haselmeier sees itself as a strategic partner to pharmaceutical and biotechnological companies for the development and production of innovative application aids which are intended to bring relief to patients' lives and improve their quality of life across the board.

The Pergoveris® pen for Merck represents a further innovative self-injection system from Haselmeier for treating women who want to conceive, to add to its other pre-filled, ready-to-use pen injection aids. The advantages of the new pen which is available in three dosage strengths of 300 IU, 450 IU and 900 IU are obvious: The ease of operation has been significantly improved, and it now offers patients the highest level of safety in administering the drug – correctly mixed with the right dosage. Added to this is the fact that doctors can now respond even better to the particular needs of their patients as the dosage can be adjusted in steps of 12.5 IU during treatment.

Dr. Sascha Pohl, Deputy Development Manager at Haselmeier: *"This is an important step for Merck and Haselmeier which we can both be proud of. We are enabling our customer Merck to maintain its Family of Pens™ series on the market with a worthy successor. This generation of pens has again succeeded in exceeding patients' needs. It's a nice feeling to be able to make your own contribution through your commitment to project planning."*

About Haselmeier

Haselmeier stands for the development and production of innovative self-injection devices with award-winning designs. The Haselmeier Group primarily works under the authority of pharmaceutical and biotechnology companies to improve the lives of patients by manufacturing pen and auto-injectors that are easy to use and that can be dosed with precision. The family business covers all steps - from design to planning to industrialisation - in the creation of high-quality self-injection systems.

Founded as early as in 1920 in Stuttgart, Haselmeier has long been an established name in the med-tech industry, thanks to its proprietary technologies and international award-winning designs. In three years from now, this well-established company will be able to look back on a 100 year-old success story. Spread across eight global locations on three different continents, the Haselmeier Group employs a workforce of about 200 employees. While the Development department is located in Stuttgart, Haselmeier products are now manufactured in the most modern production facilities in Buchen in Odenwald (Germany), Dnešice (Czech Republic) and Bengaluru (India). The Head Office is in Zurich (Switzerland), and there are further sales offices in Lowell, Massachusetts (USA), Gurgaon (India) and Guangzhou (China).

For further information, please go to: www.haselmeier.com

Characters with spaces: 3,328